Skip to content
Menu

Roth Capital Reiterates Buy on Annovis Bio, Lowers Price Target to $3

Benzinga Newsdesk 3 days ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Roth Capital analyst Boobalan Pachaiyappan reiterates Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $7 to $3.

Roth Capital analyst Boobalan Pachaiyappan reiterates Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $7 to $3.

Read at benzinga.com